Skip to main content

Table 1 Ovarian cancer patient characteristics

From: miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway

  Histological subtype FIGO stage Grade Cytotoxic agents used Response to last Pt containing treatment
Patient 1 Serous IV 2 Carboplatin, Paclitaxel PD within 1 month
Patient 2 Serous IIIc UK Carboplatin, Paclitaxel, Gemcitabine PD within 4 months
Patient 3 Serous IIIc 3 Carboplatin, Paclitaxel, Gemcitabine PD within 1 month
Patient 4 Serous IIIc 2 Carboplatin, Paclitaxel, Olaparib, Caelyx PD during treatment
Patient 5 Clear cell IIIc 3 Carboplatin, Ifosfamide PD within 1 month
Patient 6 Serous IIIc 3 Carboplatin, Paclitaxel, Caelyx PD within 5 months
Patient 7 Serous IIIc 2   Chemotherapy naive
  1. UK: Unknown, Pt: Platinum, PD: Progressive disease, Caelyx: liposomal doxorubicin